Cord Blood News Volume 14.00 | Jan 6 2021

May 12, 2022

116

2022-01-06 | CBN 14.00

Cord Blood News by STEMCELL Technologies

Vol. 14.00 – 6 January, 2022

TOP STORY

Maternal Mid-Gestational and Child Cord Blood Immune Signatures Are Strongly Associated with Offspring Risk of ASD

Investigators measured levels of 60 cytokines and growth factors in 869 maternal mid-gestational and 807 child cord blood plasma samples from 457 autism spectrum disorders and 497 control children from the Norwegian Autism Birth Cohort.
[Molecular Psychiatry]

Abstract

Dr. Daniel Dever, describes a CRISPR-Cas9-based protocol for gene editing hematopoietic stem cells in this on-demand webinar.

PUBLICATIONSRanked by the impact factor of the journal

Intramuscular and Intratendinous Placenta-Derived Mesenchymal Stromal-Like Cell Treatment of a Chronic Quadriceps Tendon Rupture

The quadriceps tendon was reconstructed applying a conventional suture anchor repair procedure combined with a synthetic mesh augmentation and additional intramuscular and intratendineous placenta-derived adherent mesenchymal stromal-like cell injections as an individualized treatment approach.
[Journal of Cachexia Sarcopenia and Muscle]

Abstract

Evaluation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Conditioning Medium (hWJ-MSCs-CM) or Scorpion Venom Breast Cancer Cell Line In Vitro

Researchers evaluated the anticancer potential of Egyptian scorpion Leiurus quinquestriatus venom or human Wharton’s jelly-derived mesenchymal stem cells conditioning medium/conditioning medium against breast cancer cell line as an alternative effective cancer biotherapy.
[Theranostics]

Abstract

HLA 1–3 Antigen-Mismatched Related Peripheral Blood Stem Cells Transplantation Using Low-Dose Antithymocyte Globulin versus Unrelated Cord Blood Transplantation

Scientists evaluated 7861 patients with hematologic malignancies who received either a cord blood transplant without anti-thymocyte globulin (ATG) or an HLA 1-3 antigen–mismatched related donor peripheral blood stem-cell transplantation using low-dose ATG.
[American Journal of Hematology]

Abstract

Expression Profiling of lncRNAs and mRNAs in Placental Site Trophoblastic Tumor (PSTT) by Microarray

The expression levels of long noncoding RNAs and mRNAs in four human placental site trophoblastic tumor tissues and four normal placental villi were investigated.
[International Journal of Medical Sciences]

Full Article Graphical Abstract

Human Umbilical Cord Mesenchymal Stem Cells Improve the Necrosis and Osteocyte Apoptosis in Glucocorticoid-Induced Osteonecrosis of the Femoral Head Model through Reducing the Macrophage Polarization

The protein expression of AKT, mTOR, p-AKT and p-mTOR was detected using western blot assay. The results showed that human umbilical cord mesenchymal stem cells treatment prominently promoted the glucocorticoid-induced the decrease of the collagen level and the increase of TRAP positive cells.
[International Journal of Stem Cells]

Abstract

Diesel Exhaust Particles Impair Therapeutic Effect of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells against Experimental Colitis through ROS/ERK/cFos Signaling Pathway

Researchers reported the effects of diesel exhaust particles exposure on the properties of human Wharton’s jelly-derived mesenchymal stem cells, including stemness, regeneration, and immunomodulation.
[International Journal of Stem Cells]

Abstract

Return to your lab safely and efficiently with these guides and resources so that you can focus more on moving your research goals forward.

REVIEWS

Hematopoietic Stem Cell Gene Editing and Expansion: State-of-the-Art Technologies and Recent Applications

Scientists present a summary and discussion of the implications of new approaches to improve hematopoietic stem cell transplantation-based therapy.
[Experimental Hematology]

Abstract

INDUSTRY AND POLICY NEWS

Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).
[Celularity, Inc.]

Press Release

FEATURED EVENT

Maternal Mid-Gestational and Child Cord Blood Immune Signatures Are Strongly Associated with Offspring Risk of ASD

Intramuscular and Intratendinous Placenta-Derived Mesenchymal Stromal-Like Cell Treatment of a Chronic Quadriceps Tendon Rupture

Evaluation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Conditioning Medium (hWJ-MSCs-CM) or Scorpion Venom Breast Cancer Cell Line In Vitro

HLA 1–3 Antigen-Mismatched Related Peripheral Blood Stem Cells Transplantation Using Low-Dose Antithymocyte Globulin versus Unrelated Cord Blood Transplantation

Expression Profiling of lncRNAs and mRNAs in Placental Site Trophoblastic Tumor (PSTT) by Microarray

Human Umbilical Cord Mesenchymal Stem Cells Improve the Necrosis and Osteocyte Apoptosis in Glucocorticoid-Induced Osteonecrosis of the Femoral Head Model through Reducing the Macrophage Polarization

Diesel Exhaust Particles Impair Therapeutic Effect of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells against Experimental Colitis through ROS/ERK/cFos Signaling Pathway

Hematopoietic Stem Cell Gene Editing and Expansion: State-of-the-Art Technologies and Recent Applications

Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

5^th International Cancer Symposium

> See All Events

Faculty Position – Molecular Therapeutics

Postdoctoral Associate – Molecular and Cellular Biology

Clinical Research Manager – Leukemia Clinical Trials

Postdoctoral Scholar Position – Regeneration

Research Technician – Hematologic Disorders

> See All Jobs